Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>/=18 years~* First chronic phase, less than 6 months of duration~* Intermediate Sokal's risk~* Ph positive~* No previous treatment or hydroxiurea only.~* Performance status (ECOG/WHO) \< or = 2~* Written informed consent~Exclusion Criteria:~* Age \<18~* Low or high Sokal risk score.~* More than 6 months from diagnosis.~* Second chronic, accelerated or blastic phase~* Scheduled allogeneic stem cell transplantation within 1 year from diagnosis.~* Performance status (ECOG/WHO) \> 2 (see Appendix 2)~* Inability to provide written informed consent~* Pregnancy~* Formal refusal of any recommendation of a safe contraception~* Alcohol or drug addiction~* Altered hepatic or renal function as defined by AST/ALT or bilirubine \> 3 times upper normal limits (UNL) and by creatinine ³ 20mg/L Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).